Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oscient to acquire Reliant heart drug
Antara (fenofibrate) is indicated as an adjunct treatment for hypercholesterolemia and hypertriglyceridemia in combination with diet. Clinical studies have shown that Antara along with a healthy diet is
Antara (fenofibrate) is indicated as an adjunct treatment for hypercholesterolemia and hypertriglyceridemia in combination with diet. Clinical studies have shown that Antara along with a healthy diet is
Under the agreement, Schering-Plough Research Institute (SPRI), the R&D arm of Schering-Plough, will provide both scientific guidance and funding as Hurel continues its one-year R&D program aimed at
Diabetes is a major risk factor for cardiovascular death in transplant patients. The study results suggest that immunosuppressant efficacy is not the only factor to affect the long-term
AC-100 is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells. The peptide demonstrated a favorable safety profile in the trial
VGV-1 is a suspension of thymus nuclear protein given through intramuscular injection. Results indicate statistically significant reductions in viral load in some patients, only mild adverse events attributed
PerkinElmer’s collaboration with the Johns Hopkins University and the University of Birmingham is expected to expand cancer research capabilities by giving key opinion leaders advanced tools, technology and
Under the revised terms, Depomed has been granted co-promotion rights, which will enable Depomed to promote the product through its own sales force or through a contract sales
Under the terms of the agreement, Albany Molecular Research (AMRI) will manufacture the active pharmaceutical ingredient in New River’s NRP104, an investigational treatment for ADHD that is currently
The amendment extends the exclusive option agreement an additional year and will expire on December 6, 2007 beyond the anticipated date of a new drug application (NDA) filing
Genzyme is also currently conducting approval-qualifying manufacturing runs of Cerezyme and Myozyme at the facility. Myozyme, which is currently manufactured in the US, was approved this year in